Patents by Inventor Andrew S. Judd

Andrew S. Judd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8242139
    Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: August 14, 2012
    Assignee: Abbott Laboratories
    Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. Iyengar, Philip R. Kym, Andrew J. Souers
  • PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES
    Publication number: 20110281842
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
    Type: Application
    Filed: May 12, 2011
    Publication date: November 17, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael R. Michaelides, Andrew S. Judd, Shannon R. Fix-Stenzel, Richard F. Clark, Bryan K. Sorensen, Zhiqin Ji
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7834012
    Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: November 16, 2010
    Assignee: Abbott Laboratories
    Inventors: Zhonghua Pei, Thomas von Geldern, David J. Madar, Xiaofeng Li, Fatima Basha, Hong Yong, Kenton L. Longenecker, Bradley J. Backes, Andrew S. Judd, Mathew M. Mulhern, Kent D. Stewart
  • Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme
    Publication number: 20080312282
    Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: April 30, 2008
    Publication date: December 18, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. Iyengar, Philip R. Kym, Andrew J. Souers
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Patent number: 7119205
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: October 10, 2006
    Assignee: Abbott Laboratories
    Inventors: Rajesh R. Iyengar, Andrew S. Judd, Gang Zhao, Philip R. Kym, Hing L. Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard F. Clark, Ernst U. Frevert, Barbara L. Cool, Tianyuan Zhang, Robert F. Keyes, Todd M. Hansen, Zhili Xin
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7071182
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 4, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7049307
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 23, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka